Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.
about
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolismOnce versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolismPrevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesIncidence and cost burden of post-thrombotic syndromePharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacementPrevention of thromboembolism with low-molecular-weight heparin in orthopedic surgery: a 5-year experience.Meta regression analysis to indirectly compare dalteparin to enoxaparin for the prevention of venous thromboembolic events following total hip replacement.Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange.Genome-wide copy number variation association study suggested VPS13B gene for osteoporosis in CaucasiansTherapeutic equivalency of low-molecular-weight heparins.Once versus twice daily LMWH for the initial treatment of venous thromboembolism.The METHRO trials.Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.Ximelagatran, a new oral direct thrombin inhibitor, for the prevention of venous thromboembolic events in major elective orthopaedic surgery. Efficacy, safety and anaesthetic considerations.Evidence for extended prophylaxis in the setting of orthopedic surgery.Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management.Major bleeding rates after prophylaxis against venous thromboembolism: systematic review, meta-analysis, and cost implications.Ximelagatran in orthopaedic surgery.Management and prevention of venous thromboembolism including surgery and the pregnant state.Compliance with Surgical Care Improvement Project measures and hospital-associated infections following hip arthroplastyLow dose compared to variable dose Warfarin and to Fondaparinux as prophylaxis for thromboembolism after elective hip or knee replacement surgery; a randomized, prospective study.Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement.Clinical use of parnaparin in major and minor orthopedic surgery: a review.Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplastyA rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry.Factors affecting perioperative blood loss and transfusion rates in primary total joint arthroplasty: a prospective analysis of 1642 patients.Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis.High incidence of complications from enoxaparin treatment after arthroplasty.Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.State-of-the-art review: Assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis.Pre-operative pulmonary assessment for patients with hip fracture.Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulantsWarfarin for venous thromboembolism prophylaxis after elective hip or knee arthroplasty: exploring the evidence, guidelines, and challenges remaining.The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.Venous Thromboembolism Prophylaxis in Liver Surgery.Differentiation of parenteral anticoagulants in the prevention and treatment of venous thromboembolism.Regarding clinical practice guidelines on the use of warfarin.Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
P2860
Q24201186-72B5EB22-6614-4A23-AFD2-0B774827AD72Q24246284-16CFB8B0-DB41-4769-BB9B-BA2319CF1F96Q24632872-E0C0F86D-7AA3-4017-B504-C608B97BC924Q28235459-79187C58-4D9B-4D64-A389-D962A29CF8C6Q28245267-4DBE5D29-E6CC-40AC-93F0-571748721A71Q33359673-189E7028-1D6F-4AF9-8A0D-CFCB71377062Q33393874-750BCD4F-D724-4DAB-B53E-DD82F72AF6BCQ33402042-94C24373-69A0-489A-9E66-DA7E882E0C50Q33685447-200F5868-522C-4075-8538-52F613EF9639Q34075548-27BEE5E1-66B5-421C-96B6-A9C298AAF959Q34648639-DA85030F-6C49-4819-BF45-AE44A32955C8Q35048657-B26C1975-B1D6-47E1-8E13-DF6141B25F80Q35117100-CE16D977-209E-4274-B8D2-10B52BD226C1Q35160253-AC6DF232-8154-41DE-AB88-0EB219CA73D4Q35843864-C94EC8D0-1A77-4E1F-B811-348690503CF2Q35866089-CB4426AF-E0D5-41CE-AD3E-16717EE6BD17Q35878355-A477E996-8772-4B68-9B9C-6E589261B812Q35989224-A7A07963-3819-4619-BB00-D203E5E0D792Q36090077-10DDFD80-CB0D-42E5-B73F-88FB48279E45Q36101662-D5F9C1C9-EB03-4F81-AEDB-5A9E2D2D524AQ36106181-75B383AD-D477-436D-888D-78AFDCE59866Q36131612-135EC781-2073-4A92-A18E-9816E79C0EE9Q36232265-F6B26E90-A6BB-4749-89B8-408DABBC0A27Q37019860-2471BCCF-B8F1-4F26-A0D2-0D010ED038CAQ37081079-F0A8A64F-9754-4EC4-B85D-6BF738F3E09FQ37087333-BC982B82-200A-48C6-9855-0C71CFA9A53AQ37156956-6EEC1751-D753-4704-BFED-B9C4C04617D0Q37299930-21E6E8A3-97D0-4F22-8612-317E1A46F89AQ37314088-187648D7-0FE0-43B8-871E-93F82F233D7EQ37483311-9D0518D5-3FB3-49CB-94B0-0CF28605E3B3Q37490581-567ABB81-DE8A-4D0A-A256-3D2D03DBFFFDQ37553571-29074FAD-500B-43ED-802C-1D8AA6EECAADQ37807916-420B925F-EBBF-499E-AF3B-059F15B40378Q37956637-651F8EFD-AFEB-4789-9A64-65035D967C00Q37971832-1904874A-B46D-460A-844E-6437B0D61615Q37990316-5EA4FBC5-4784-4DF3-BC92-15B7EA6CD616Q38613357-59323BB7-8A7A-4FBC-973B-BAEFEBBD8A71Q42718620-62C74C10-F58C-4507-A4D1-40088AB9B5A5Q43530498-0D47DADC-8891-4CE1-979E-1BC48FFADC28Q43982844-D452782C-59D5-41AE-8D2C-A73BC9879312
P2860
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Low-molecular-weight heparin p ...... n Fragmin Trial Investigators.
@en
Low-molecular-weight heparin p ...... n Fragmin Trial Investigators.
@nl
type
label
Low-molecular-weight heparin p ...... n Fragmin Trial Investigators.
@en
Low-molecular-weight heparin p ...... n Fragmin Trial Investigators.
@nl
prefLabel
Low-molecular-weight heparin p ...... n Fragmin Trial Investigators.
@en
Low-molecular-weight heparin p ...... n Fragmin Trial Investigators.
@nl
P2093
P1476
Low-molecular-weight heparin p ...... n Fragmin Trial Investigators.
@en
P2093
Bergqvist D
Fellenius C
Holmqvist A
P304
P356
10.1001/ARCHINTE.160.14.2199
P407
P577
2000-07-01T00:00:00Z